PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

LS. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TRACE MANUEL Stitute for form 1449APTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known				
Application Number	10/617,888			
Filing Date	July 14, 2003			
First Named Inventor	Donald J. ZACK			
Art Unit	1632			
Examiner Name	TBA	_		
Attorney Docket Number	001107.00369			

U.S. PATENT DOCUMENTS					
	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
	No.1	Number - Kind Code <sup>2</sup> (If known)	MM-DD-YYYY		Passages or Relevant Figures Appear
ML		US-5,874,082	01/21/1999	De Boer	
ML		US- 6,509,016	01/21/2003	Chatterjee et al.	
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Cite	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*	No.1	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>8</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document		T <sup>6</sup>
	· · · · · · · · · · · · · · · · · · ·					

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
ML		Phillips, K.E. et al. "IL-2Ra-Directed Monoclonal Antibodies Provide Effective Therapy in a Murine Model of Adult T-Cell Leukemia by a Mechanism Other than Blockade of IL-2/IL-2Ra Interaction," Cancer Research (Dec 15 2000), pp 6977-6984, Vol. 60			
ML		Yamada, T. et al. "Further Characterization of a Monclonal Antibody Recognizing Apolipoprotein E Peptides in Amyloid Deposits," Annals of Clinical and Laboratory Science (July/August 1997), pp. 276-281, Vol. 27, No. 4			
ML		Mogi, M. et al., "b2-Microglobulin decrease in cerebrospinal fluid from Parkinsonian patients," Neuroscience Letters (Sept 25, 1989), Vol. 104, No. 1-2, pp. 241-246			
		International Search Report PCT/US03/21738, dated July 1, 2004			

	()				
Examiner Signature	waric	Leaville	•	Date Considered	03-14-0,6

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patient Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.